Impact of achieving glycated hemoglobin targets on cardiovascular events/mortality: Post-hoc analysis of the nephropathy in diabetes type 2 trial

Table 2 Comparison between outcome events among multifactorial intensive therapy and standard of care group, n (%)

Variable	Overall population (n = 323)	SoC group (n = 139)	MT group (n = 184)	P value
MACE	190 (58.8)	97 (69.8)	93 (50.5)	< 0.001
Myocardial infarction	38 (11.8)	18 (12.9)	20 (10.9)	0.211
TIA/stroke	18 (5.6)	10 (7.2)	8 (4.3)	0.885
Revascularization	10 (3.1)	9 (6.5)	1 (0.5)	0.032
Major amputation	0 (0)	0 (0)	0 (0)	1.000
Cardiovascular death	124 (38.4)	60 (43.2)	64 (34.8)	0.126
All-cause death	139 (43.0)	67 (48.2)	72 (39.1)	0.104

MT: Multifactorial intensive therapy; SoC: Standard of care; MACE: Major adverse cardiovascular events; TIA: Transient ischemic attack. Categorical variables are presented as n (%) and compared using Pearson’s χ² test.